CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) Files An 8-K Results of Operations and Financial Condition
Item 2.02
CATALYST BIOSCIENCES, INC. Exhibit
EX-99.1 2 d843140dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Catalyst Biosciences Reports Fourth Quarter and Full-Year 2019 Operating & Financial Results and Provides a Corporate Update Presented positive clinical and pre-clinical data from its MarzAA and DalcA hemophilia programs Announced a global license and collaboration agreement with Biogen to develop and commercialize pegylated CB 2782 for Dry AMD SOUTH SAN FRANCISCO,…
To view the full exhibit click here
About CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO)
Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.